These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26177509)

  • 41. Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.
    Yan H; Wen L; Tan D; Xie P; Pang FM; Zhou HH; Zhang W; Liu ZQ; Tang J; Li X; Chen XP
    Oncotarget; 2017 Jan; 8(1):1529-1540. PubMed ID: 27903973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
    Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
    Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia.
    Xiao W; Chan A; Waarts MR; Mishra T; Liu Y; Cai SF; Yao J; Gao Q; Bowman RL; Koche RP; Csete IS; DelGaudio NL; Derkach A; Baik J; Yanis S; Famulare CA; Patel M; Arcila ME; Stahl M; Rampal RK; Tallman MS; Zhang Y; Dogan A; Goldberg AD; Roshal M; Levine RL
    Blood; 2021 Mar; 137(10):1377-1391. PubMed ID: 32871587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.
    Chen F; Ishikawa Y; Akashi A; Naoe T; Kiyoi H
    Oncotarget; 2016 Jul; 7(30):47018-47032. PubMed ID: 27331411
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minimal residual disease-directed therapy in acute myeloid leukemia.
    Kayser S; Schlenk RF; Grimwade D; Yosuico VE; Walter RB
    Blood; 2015 Apr; 125(15):2331-5. PubMed ID: 25631772
    [No Abstract]   [Full Text] [Related]  

  • 48. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
    Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.
    Wunderlich M; Mizukawa B; Chou FS; Sexton C; Shrestha M; Saunthararajah Y; Mulloy JC
    Blood; 2013 Mar; 121(12):e90-7. PubMed ID: 23349390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis.
    Jalili M; Yaghmaie M; Ahmadvand M; Alimoghaddam K; Mousavi SA; Vaezi M; Ghavamzadeh A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):325-329. PubMed ID: 29479958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
    Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
    Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
    Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
    Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
    Parsa-Kondelaji M; Ayatollahi H; Rostami M; Sheikhi M; Barzegar F; Afzalaghaee M; Moradi E; Sadeghian MH; Momtazi-Borojeni AA
    J Cell Mol Med; 2022 Jul; 26(13):3797-3801. PubMed ID: 35692075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
    Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
    Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.
    Greif PA; Hartmann L; Vosberg S; Stief SM; Mattes R; Hellmann I; Metzeler KH; Herold T; Bamopoulos SA; Kerbs P; Jurinovic V; Schumacher D; Pastore F; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Graf A; Krebs S; Blum H; Neumann M; Baldus CD; Bohlander SK; Wolf S; Görlich D; Berdel WE; Wörmann BJ; Hiddemann W; Spiekermann K
    Clin Cancer Res; 2018 Apr; 24(7):1716-1726. PubMed ID: 29330206
    [No Abstract]   [Full Text] [Related]  

  • 59. Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.
    Khoury H; He R; Schimmer A; Beadle JR; Hostetler KY; Minden MD
    Chemotherapy; 2018; 63(4):225-237. PubMed ID: 30372692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.